Immune-Related Molecular Profiling of Thymoma With Myasthenia Gravis

Jinman Zhuang1,2,3, Maohao Guan4, Maolin Liu1,2,3, Yuhang Liu1,2,3, Shuyan Yang1,2,3, Zhijian Hu1,2,3, Fancai Lai4* and Fei He1,2,3*

1Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China, 2Fujian Provincial Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China, 3Fujian Digital Tumor Data Research Center, Fuzhou, China, 4Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Background: Approximately 50% of thymoma patients also show myasthenia gravis (MG), which is an autoimmune disease; however, the pathogenesis of MG-associated thymoma remains elusive. Our aim was to investigate immune-related lncRNA profiles of a set of candidate genes for better understanding of the molecular mechanism underlying the pathogenesis of thymoma with or without MG.

Methods: Molecular profiles of thymoma with or without MG were downloaded from The Cancer Genome Atlas, and Pearson’s correlation analysis was performed to identify immune-related lncRNAs. T test was used to examine the differential expression and differential methylation between thymoma patients with or without MG. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to predict the function of target genes of immune-related lncRNAs.

Results: Analyses of the 87 thymoma samples with complete MG information revealed that 205 mRNAs and 56 lncRNAs showed up-regulated expression in thymoma with MG patients, while 458 mRNAs and 84 lncRNAs showed down-regulated expression. The methylation level of three immune-related lncRNAs (AP000787.1, AC004943.1, WT1-AS, FOXG1-AS1) was significantly decreased in thymoma tissues, and the methylation level of these immune-related lncRNAs (WT1-AS: Cor = 0.368, p < 0.001; FOXG1-AS1: Cor = 0.288, p < 0.01; AC004943.1: Cor = -0.236, p < 0.05) correlated with their expression. GO and KEGG pathway analysis revealed that targets of the immune-related lncRNA FOXG1-AS1 were enriched in small GTPase binding and herpes simplex virus 1 infection. Transcription coregulator activity and cell cycle were the most enriched pathways for targets of lncRNA AC004943.1. LncRNA WT1-AS targets were most enriched in actin binding and axon guidance.

Conclusion: Our results revealed the immune-related molecular profiling of thymoma with MG and without MG and identified key pathways involved in the underlying molecular mechanism of thymoma-related MG. These findings provide insights for further research of potential markers for thymoma-related MG.

Keywords: thymoma, mg, bioinformatics, immune-related lncRNAs, functional enrichment analysis
INTRODUCTION

Thymoma is the most common anterior mediastinal tumor in adults, and approximately 50% of thymoma patients show myasthenia gravis (MG) (Garibaldi et al., 2020). Thymectomy is effective for thymoma-associated MG, but the symptoms of some patients remain the same or become worse after surgical treatment (Kato et al., 2020). Although a link between thymoma and MG has long been established, the cause of thymoma-related MG remains elusive. For example, even among patients with similar age, sex, social-economic situation and histological types, some thymoma patients show MG while others do not show MG. Therefore, genetic factors may contribute to the development of MG-associated thymoma.

MG is an autoimmune disease associated with thymus abnormalities that are characterized by rapid skeletal muscle fatigue (Kumar, 2015). Thymoma-related MG is associated with abnormalities of the thymus, an important lymphoid organ that is closely related to immunity. Immune-related genes play an important function in the progression of tumors and these immune-related proteins remodel the tumor microenvironment through synergistic effects with other cytokines (Raica, Cimpean, & Ribatti, 2008; Chen, Qin, & Liu, 2020). Thymoma-related MG is usually more severe compared with generalized disease and is associated with bulbar and respiratory symptoms (Evoli et al., 2002). Previous studies showed that thymoma-related MG is likely mediated by dysfunctions in immunoregulation (Shelly, Agmon-Levin, Altman, & Shoenfeld, 2011; Bernard et al., 2016).

Long noncoding RNAs (lncRNAs) function in many biological processes, including transcriptional regulation and cell differentiation (Ponting, Oliver, & Reik, 2009), and play vital roles in cancer immunity (Yu, Wang, He, Xu, & Wang, 2018). Research has identified several lncRNAs implicated in MG (Barzago et al., 2016), and several aberrantly expressed lncRNAs were found in MG with thymoma (Luo et al., 2015; Niu, Jiang, Yin, & Hu, 2020). Hypomethylation and hypermethylation are common mechanisms underlying the aberrant expression of lncRNAs, which further impacts the regulation of their target genes. However, few studies have investigated the regulatory mechanisms of lncRNAs in thymoma-associated MG compared with thymoma without MG. Further understanding of the roles of immune-related lncRNAs in the molecular mechanism of thymoma patients with MG will be of great significance in the management of patients in the clinic.

Our current study aimed to investigate the potential underlying molecular mechanism of immune-related lncRNAs in the pathogenesis of thymoma-related MG using The Cancer Genome Atlas (TCGA) dataset. We investigated the differential expression and methylation profiles of thymoma patients with MG and without MG.

| TABLE 1 | Patient characteristics of the two groups of thymoma patients. |

| Characteristics                              | Patient group, n (%)                      | χ²    | P     |
|----------------------------------------------|------------------------------------------|-------|-------|
|                                              | Thymoma with MG (n = 29)                 |       |       |
| Age (n = 87)                                 |                                          |       |       |
| ≤60 years                                    | 17 (58.6)                                 | 1.472 | 0.225 |
| >60 years                                    | 12 (41.4)                                 |       |       |
| Gender (n = 87)                              |                                          |       |       |
| Male                                         | 14 (48.3)                                 | 0.092 | 0.762 |
| Female                                       | 15 (51.2)                                 |       |       |
| Race (n = 86)                                |                                          | 2.573 | 0.276 |
| White                                        | 24 (85.7)                                 |       |       |
| Asian                                        | 4 (14.3)                                  |       |       |
| Black                                        | 0 (0.0)                                   |       |       |
| History of malignancy (n = 87)               |                                          | 1.243 | 0.265 |
| No                                           | 28 (96.5)                                 |       |       |
| Yes                                          | 1 (3.5)                                   |       |       |
| WHO classification (n = 87)                  |                                          | 15.281| 0.009 |
| A                                            | 3 (10.3)                                  |       |       |
| AB                                           | 6 (20.7)                                  |       |       |
| B1                                           | 2 (6.9)                                   |       |       |
| B2                                           | 13 (44.8)                                 |       |       |
| B3                                           | 5 (17.2)                                  |       |       |
| C                                            | 0 (0.0)                                   |       |       |
| Masaoka stage (n = 87)                       |                                          | 4.947 | 0.422 |
| I                                            | 8 (27.6)                                  |       |       |
| IIa                                          | 12 (41.4)                                 |       |       |
| IIb                                          | 5 (17.2)                                  |       |       |
| III                                          | 3 (10.3)                                  |       |       |
| IVa                                          | 1 (3.5)                                   |       |       |
| IVb                                          | 0 (0.0)                                   |       |       |
TABLE 2 | Differentially expressed immune-related gene pairs.

| mRNA | logFC | IncRNA | logFC | Correlation coefficient | P     |
|------|-------|--------|-------|-------------------------|-------|
| CCL20| -7.018592748 down | HOXC-AS1 | -3.486290741 down | 0.698 | 0.000 |
| CCL20| -7.018592748 down | AL691482.3 | -4.331371618 down | 0.688 | 0.000 |
| CCL20| -7.018592748 down | AC011700.1 | -4.090216284 down | 0.688 | 0.000 |
| CCL20| -7.018592748 down | DLGAP1-AS5 | -5.027264466 down | 0.602 | 0.000 |
| CCL20| -7.018592748 down | AC124248.1 | -2.012883266 down | 0.716 | 0.000 |
| CCL20| -7.018592748 down | NAALADL2-AS2 | -4.863497438 down | 0.813 | 0.000 |
| CCL20| -7.018592748 down | HOXC-AS2 | -3.774436195 down | 0.726 | 0.000 |
| CCL20| -7.018592748 down | AC013640.1 | -3.160517281 down | 0.667 | 0.000 |
| CD24| -3.828638114 down | CASC8 | -2.116289906 down | 0.909 | 0.000 |
| CD24| -3.828638114 down | AC023886.1 | -5.253853447 down | 0.917 | 0.000 |
| CD24| -3.828638114 down | AC078993.1 | -2.874110729 down | 0.924 | 0.000 |
| CD24| -3.828638114 down | LL22NC03-63E9.3 | -2.04428945 down | 0.744 | 0.000 |
| CD24| -3.828638114 down | AC012123.1 | -2.072013437 down | 0.625 | 0.000 |
| CD24| -3.828638114 down | AL691482.3 | -4.331371618 down | 0.882 | 0.000 |
| CD24| -3.828638114 down | AP001150.1 | -3.073247043 down | 0.831 | 0.000 |
| CD24| -3.828638114 down | AC025580.1 | -5.291768385 down | 0.932 | 0.000 |
| DEFB4A| -6.61740337 down | AC104365.1 | -3.042337304 down | 0.987 | 0.000 |
| DEFB4A| -6.61740337 down | TMEM132D-AS1 | -6.646505893 down | 0.993 | 0.000 |
| DEFB4A| -6.61740337 down | LSAMP-AS1 | -2.021421143 down | 0.909 | 0.000 |
| DEFB4A| -6.61740337 down | EGFLAM-AS4 | -4.460946345 down | 0.992 | 0.000 |
| DEFB4A| -6.61740337 down | SLC04A1-AS1 | -3.962515293 down | 0.941 | 0.000 |
| LTF | -3.712976488 down | AC104365.1 | -3.042337304 down | 0.980 | 0.000 |
| LTF | -3.712976488 down | TMEM132D-AS1 | -6.646505893 down | 0.984 | 0.000 |
| LTF | -3.712976488 down | LSAMP-AS1 | -2.021421143 down | 0.935 | 0.000 |
| LTF | -3.712976488 down | EGFLAM-AS4 | -4.460946345 down | 0.981 | 0.000 |
| LTF | -3.712976488 down | SLC04A1-AS1 | -3.962515293 down | 0.959 | 0.000 |
| IL12A | -2.200880413 down | AC022762.1 | -2.219385719 down | 0.791 | 0.000 |
| IL12A | -2.200880413 down | AL160191.1 | -2.442168709 down | 0.844 | 0.000 |
| IL12A | -2.200880413 down | PCAT7 | -2.96040145 down | 0.798 | 0.000 |
| IL12A | -2.200880413 down | AP000526.1 | -2.008528258 down | 0.786 | 0.000 |
| IL12A | -2.200880413 down | AC100823.1 | -2.789794422 down | 0.771 | 0.000 |
| IL12A | -2.200880413 down | LINC01587 | -2.011010842 down | 0.814 | 0.000 |
| IL12A | -2.200880413 down | AL137804.1 | -2.516876723 down | 0.788 | 0.000 |
| CXCL13 | -2.267398065 down | AC104248.1 | -2.176317388 down | 0.647 | 0.000 |
| CXCL13 | -2.267398065 down | AC106882.1 | -2.09002912 down | 0.710 | 0.000 |
| PYDC1 | -2.267398065 down | FAM222A-AS1 | -4.157505836 down | 0.959 | 0.000 |
| PYDC1 | -2.267398065 down | CASC19 | -2.953486218 down | 0.826 | 0.000 |
| PYDC1 | -2.267398065 down | AC022509.1 | -2.279085229 down | 0.954 | 0.000 |
| PYDC1 | -2.267398065 down | AC013640.1 | -3.160517281 down | 0.655 | 0.000 |
| IL31RA | 2.700590226 up | AC005532.1 | 2.407791325 up | 0.651 | 0.000 |
| IL31RA | 2.700590226 up | AC055847.1 | 3.475440443 up | 0.620 | 0.000 |
| IL31RA | 2.700590226 up | AL392089.1 | 2.435860003 up | 0.608 | 0.000 |
| IL31RA | 2.700590226 up | AC004160.2 | 2.185213075 up | 0.603 | 0.000 |
| IL31RA | 2.700590226 up | AC079467.1 | 2.3016293 up | 0.686 | 0.000 |
| IL31RA | 2.700590226 up | AL035425.3 | 2.554999873 up | 0.650 | 0.000 |

MATERIALS AND METHODS

Data Collection

DNA methylation data of 94 thymoma cases (normal: n = 2; tumor: n = 92) and RNA-seq of 92 cases (normal: n = 2; tumor: n = 90) were downloaded from TCGA (https://portal.gdc.cancer.gov/). The clinical data of the patients were also downloaded.

Human Genome Annotated Data (GRCh38) were used to annotate to gene ID (https://asia.ensembl.org/index.html). Immune-related gene sets IMMUNE_RESPONSE (Immune response M19817) and IMMUNE_SYSTEM_PROCESS (Immune system process M13664) were downloaded from the Gene Set Enrichment Analysis (GSEA) (http://www.gsea-msigdb.org/gsea/index.jsp).

Frontiers in Genetics | www.frontiersin.org
October 2021 | Volume 12 | Article 756493
3
Zhuang et al. Immune-Related Molecular Profiling of MG
Identification of Immune-Related Genes and Immune-Related IncRNAs

Pearson’s correlation analysis was performed on immune-related genes and IncRNA expression levels in samples to identify immune-related IncRNAs according to the correlation coefficients and p values (|correlation coefficient|>0.6 and p < 0.001).

Identification of Differential Expression and Differential Methylation

R package (edgeR) was used to identify the differential expression of IncRNAs (fold change (FC) > 2, adjusted p < 0.05) and differential methylation of IncRNAs (logFC filter>0.5, adjusted p < 0.05) between thymoma patients with MG and those without.
MG. Methylation sites of immune-related lncRNAs were identified according to GRCh38.

**Function Prediction of Immune-Related lncRNAs**
The target genes of lncRNAs were identified from Pearson’s correlation analysis (|correlation coefficient|>0.4 and \( p < 0.001 \)). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to predict the functions of the target genes of the immune-related lncRNAs (\( p < 0.01 \)).

**Statistical Analysis**
Chi-square test was used to analyze the differences in clinical information between thymoma patients with MG and those without MG. R packages (limma and edgeR) were used to identify differential expression and differential methylation.

Bioconductor analyses (“org.Hs.eg.db,” “DOSE,” “pathview” and “clusterProfiler”) were performed to predict the function of immune-related lncRNAs. Data were analyzed using STATA/MP version 15.0 (StataCorp, College Station, TX, United States) and R software version 4.0.4 for Windows 10.

**RESULTS**

**Demographic Characteristics of the Patients**
We obtained DNA methylation and RNA-seq data from thymoma cases from TCGA, and 90 thymoma tumor tissues had complete methylation and RNA-seq information. We excluded three samples that were missing information on MG history. A total of 87 patients were included in our study, including 29 patients with thymoma with MG and 58 patients with thymoma without MG. Comparison of patient...
characteristics between the two groups revealed no differences in age, gender, race, history of malignancy and Masaoka stage (Table 1). However, we found a significant difference in the distribution of WHO classification ($p < 0.01$).

**Differential Expression of mRNAs and IncRNAs**

Our analyses identified 205 mRNAs and 56 IncRNAs that were up-regulated in thymoma with MG patients, while 458 mRNAs and 84 IncRNAs were down-regulated (Supplementary Table S1, Table 2 and Figure 1). Among the differentially expressed genes, there were 10 immune-related genes (up-regulated expression: $n = 2$; down-regulated expression: $n = 8$) and 112 immune-related IncRNAs (up-regulated expression: $n = 40$; down-regulated expression: $n = 72$). There were 51 pairs of immune-related mRNA-IncRNA identified in the differential expression genes. The CCL20, CD24, DEFB4A, LTF, IL12A, CXCL13, and PYDC1 mRNAs and their co-expressed immune-related IncRNAs showed down-regulated expression in thymoma patients with MG compared with thymoma patients without MG, while IL31RA mRNA and its co-expression immune-related IncRNAs showed up-regulated expression (Table 2).

**Differential DNA Methylation of Immune-Related IncRNAs**

A total of 74 differential DNA methylation sites were found between the thymoma with MG and thymoma without MG patients, and four differential DNA methylation sites were found in immune-related IncRNAs (AC004943.1, FOXG1-AS1, WT1-AS, and AP000787.1) (Figure 2). The expression of IncRNAs WT1-AS ($Cor = 0.368, p < 0.001$) and FOXG1-AS1 ($Cor = 0.288, p < 0.01$) showed positive correlations with the methylation level, while higher expression of the IncRNA AC004943.1 was correlated with a lower DNA methylation level ($Cor = -0.236, p < 0.05$) (Figure 3).
Function of the Immune-Related IncRNAs

We further examined the three immune-related IncRNAs (AC004943.1, FOXG1-AS1, WT1-AS) that showed a correlation with methylation level to predict the function of these immune-related IncRNAs that showed differential DNA methylation levels in thymoma with MG patients. GO analysis showed that the target genes of FOXG1-AS1 were most enriched in small GTPase binding, and KEGG analysis showed that herpes simplex virus 1 infection was the most enriched pathway (Figure 4, Figure 5, Figure 6). The target genes of IncRNA AC004943.1 were mostly enriched in transcription coregulator activity in GO analysis, and the most enriched pathway was cell cycle in KEGG analysis (Figure 7, Figure 8, Figure 9). Actin binding and axon guidance were the most enriched pathway of the IncRNA WT1-AS in GO analysis and KEGG analysis (Figure 10, Figure 11).

DISCUSSION

Previous studies have demonstrated an association between MG and thymoma; however, the pathogenesis of thymoma-related MG has remained elusive. In the present study, we explored the immune-related molecular profiling of thymoma with MG and without MG. We found that a series of immune-related genes and IncRNAs were differently expressed in thymoma with and without MG. Our study identified four differential DNA methylation sites in immune-related IncRNAs (AC004943.1, FOXG1-AS1, WT1-AS and AP000787.1). We further discovered that the methylation levels of immune-related IncRNAs AC004943.1, FOXG1-AS1 and WT1-AS regulated the expression of these IncRNAs, GO and KEGG analyses revealed the functional pathways of the target genes of these immune-related IncRNAs.

CCL20, a member of CC family and the alpha subfamily chemokines, was found down-expressed in thymoma associated MG in our exploration. CCL20 was important in autoimmune disease. According to previous study, an increase of T lymphocytes may have a link to thymoma-related MG (Mishra et al., 2021), while the capacity to activate T lymphocytes were different in dendritic cells that induced by different level of CCL20 (Thomachot et al., 2004). CD24 was recognized as a genetic risk factor of multiple autoimmune disease (Tan, Zhao, Xiang, Chang, & Lu, 2016). In addition, our results also identified that the expression of CD24 is related to MG. The findings about different expression of inflammatory gene such as IL12A and IL31RA in thymoma with or without MG further confirmed the evidence that the incidence of MG may associated to infection. As Milan Radovich’s study provided, genetic alterations were have a
link to thymoma and MG (Radovich et al., 2018). Our finding further indicated that the expression of genes also alter in thymoma-related MG.

The Wilms’ tumor suppressor gene (WT1 gene) is located at 11p13, and WT1-AS is an antisense RNA that comprises 19–23 nucleotides and is complementary to WT1 (Xu, Zhang, & Zhang, 2018). A study identified an antisense regulatory region in intron 1 of the WT1 gene, located on chromosome 11p13, in Wilms’ tumors as a primary site for epigenetic deregulation (Malik et al., 2000). WT1-AS regulates its target, the WT1 gene, by binding to the TATA region of the WT1 gene promoter (Lv, Chen, Zhou, Li, & Gong, 2015). In this study, we found that DNA methylation in the promoter region of the lncRNA WT1-AS was significantly decreased in thymoma-related MG tissues compared with thymoma without MG and resulted in modulation of lncRNA expression levels, which may influence the expression of downstream genes that are related to the development of thymoma-related MG.

A clinical trial conducted in Japan reported that WT1-specific immune responses were observed in the majority of thymoma patients (Oji et al., 2018). However, the specific regulatory mechanism of WT1 in thymoma-related MG is not clear. Recent studies reported that WT1-AS is involved in the development of many diseases through its regulation of specific target genes (Le, Luo, Ouyang, & Zhong, 2020; Qiu et al., 2020; Wang, Ge, Zhang, & Chen, 2020; Wan et al., 2021). To explore the function of lncRNA WT1-AS, we performed GO and KEGG enrichment analysis. GO analysis showed that the target genes of WT1-AS were enriched in actin binding, indicating it regulates the gene expression of proteins that bind actin and thereby potentially modulates the properties and/or functions of the actin filament. Axon guidance, a significantly enriched pathway found by KEGG analysis, allows the formation of intricate neural circuits that favor axons to form synaptic connections (Russell & Bashaw, 2018; Kim & Kim, 2020). Studies have shown that disrupted axon guidance

---

**FIGURE 6** Pathway of herpes simplex virus 1 infection. Note: Visualization of a pathway significantly enriched by KEGG analysis and performed in “pathview” of R software.
contributes to neurological disorders (Niftullayev & Lamarche-Vane, 2019). As MG is an acquired autoimmune disease of nervous system that dysfunction of neuromuscular junction transmission, this result indicates that WT1-AS may function in the transmission of neuromuscular junctions and that its aberrant expression may contribute to the pathogenesis of thymoma-related MG.

FOXG1-AS1 is antisense RNA of the FOXG1 gene that is located at 14q12. Some evidence has shown that FOXG1 plays a key role in mediating cancer cell metastasis and radiosensitivity in tumors (Zheng et al., 2019; Xiao et al., 2021), but the functions of the antisense RNA FOXG1-AS1 have not been reported. Our results showed that the methylation level of lncRNA FOXG1-AS1 was lower in tumors of thymoma patients with MG, and its expression was related to the methylation level. Ras GTPases interact selectively and non-covalently with members of the Ras superfamily of monomeric GTPases. Our results identified Ras GTPase binding as one of the gene enrichment pathways of FOXG1-AS1 target genes. The Ras GTPase is a driver of many cancers, and some small GTPase proteins may bind alternative effectors that harbor Ras binding domains (Singh & Smith, 2020). Pathway analysis showed significant enrichment in herpes simplex virus 1 infection. Previous studies showed that recovery from a viral infection is regulated by the immune system (Wu, Wu, Shen, Jiang, & Xu, 2018). Persistent viral infection, especially infection from herpes simplex virus 1, is a contributing factor to some neuropathic diseases (Mangold & Szpara, 2019). In an etiological study of thymoma-associated MG, researchers found that MG might develop after pathogen infection (Cafi et al., 2014). Our results further indicated that the pathogenesis of thymoma-related MG may be associated with infection.

The methylation level of lncRNA AC004943.1 is lower in tumor tissues of thymoma patients with MG than those without MG, and its expression is down-regulated by a higher methylation level. GO and KEGG analysis revealed that the target genes of the immune-related
lncRNA AC004943.1 regulated transcription coregulator activity and cell cycle. Deregulation of the cell cycle pathway is an important hallmark of cancer. Some studies investigated the association between cell cycle proteins and thymoma and found that cell cycle protein expression regulates the pathogenesis and influences the prognosis of thymoma (Baldi et al., 2005; Mineo, Ambrogi, Mineo, & Baldi, 2005; Mineo, Ambrogi, Baldi, Pompeo, & Mineo, 2009). Transcription coregulator activity modulates the transcription of specific gene sets by binding to DNA-bound transcription factors, and thus AC004943.1 may play a role in the occurrence of thymoma with MG by influencing regulators of transcription factors.

We identified three immune-related lncRNAs (AC004943.1, WT1-AS and FOXG1-AS1) which were alter in methylation and expression, and found the target genes of these immune-related lncRNAs were enriched in “regulated transcription coregulator activity”, “cell cycle”, “actin binding”, “axon guidance”, “Ras GTPase binding” and “herpes simplex virus 1 infection”. Previous study explored the functional pathways of thymoma and thymoma-related MG have found that differential expression of functional pathways were associated to MG in different thymoma histotypes (Yamada et al., 2020). Another recent study focus on the genetic characterization of thymoma found some signal pathways that enriched by the upregulated genes in thymoma with MG may be responsible for MG in thymoma patients (Yu, Ke, Du, Yu, & Gao, 2019). In order to provide a immune-related molecular profile of thymoma-associated MG, this present study mainly explored the functional pathways of immune-related lncRNAs that their methylation and expression level were connected to the thymoma patients with MG.

The predictive value of immune-related biomarkers associated thymoma-related MG remains controversial among different reports in the literature. Our present study identified immune-related lncRNA alterations to further the molecular understanding of the occurrence and development of thymoma-related MG and provided a set of immune-related genes and lncRNAs that may aid in identifying the key biomarkers that are responsible for thymoma-related MG. These findings present insights for further research into the pathogenesis of immune-related diseases.

This study has several limitations. First, the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) lacks expression data of thymoma and the current study only used the dataset downloaded from TCGA. Therefore, we were unable
FIGURE 9 | Pathway of cell cycle. Note: Visualization of a pathway significantly enriched by KEGG analysis and performed in “pathview” of R software.

FIGURE 10 | GO analysis of WT1-AS target genes. Note: The target genes of lncRNAs were identified from Pearson’s correlation analysis (correlation coefficient \(>0.4\) and \(p<0.001\)), GO analysis were performed in “clusterProfiler” and “org.Hs.eg.db” of R software to generated these functional pathways.
to obtain confirmatory data. In addition, some samples were excluded because of incomplete clinicopathological features of the history of MG, so the sample size was limited. The precise molecular functions of these immune-related lncRNAs have not yet been validated, and future studies are required to support our findings. Furthermore, TCGA dataset lack the information of antiacetylcholine antibody which was found correlated to thymoma-related MG, it’s valuable to explore the relationship between antiacetylcholine antibody and these immune-related lncRNAs in further studies.

CONCLUSION

Our bioinformatics analysis of thymoma patients from TCGA dataset revealed a list of immune-related genes and lncRNAs for
thymoma with MG. We found that the expression of immune-related mRNA-IncRNA pairs and methylation level of immune-related IncRNAs regulated the pathogenesis of thymoma-related MG. The methylation level of several immune-related IncRNAs (AC004943.1, WT1-AS, and FOXG1-AS1) correlated with the expression levels of these IncRNAs. The target genes of the IncRNAs may regulate the occurrence of thymoma-related MG through functional pathways related to the immune system and nervous system.

DATA AVAILABILITY STATEMENT
Publicly available datasets were analyzed in this study. This data can be found here: https://CancerGenome.nih.gov/.

AUTHOR CONTRIBUTIONS
FH and FL designed the study. JZ, MG, ML, YL and SY analyzed the data. ZH and FH contributed to interpretation of the results.

REFERENCES
Baldi, A., Ambrogi, V., Mineo, D., Mellone, P., Campioni, M., Citro, G., et al. (2005). Analysis of Cell Cycle Regulator Proteins in Encapsulated Thymomas. Clin. Cancer Res. 11 (14), 5078–5083. doi:10.1186/1078-0432.CCR-05-0070
Barzago, C., Lum, J., Cavalcante, P., Srinivasan, K. G., Faggiani, E., Camera, G., et al. (2016). A Novel Infection- and Inflammation-Associated Molecular Signature in Peripheral Blood of Myasthenia Gravis Patients. Immunobiology 221 (11), 1227–1236. doi:10.1007/s00432-016-0316-0
Bernard, C., Frith, H., Pasquet, F., Kerever, S., Jamilouss, Y., Tronc, F., et al. (2016). Thymoma Associated with Autoimmune Diseases: 85 Cases and Literature Review. Autoimmun. Rev. 15 (1), 82–92. doi:10.1016/j.autrev.2015.09.005
Chen, W., Qin, Y., and Liu, S. (2020). CCL20 Signaling in the Tumor Microenvironment. Adv. Exp. Med. Biol. 1231, 53–65. doi:10.1007/978-3-030-36667-4_6
Claudio Mineo, T., Ambrogi, V., Mineo, D., and Baldi, A. (2005). Long-term Disease-free Survival of Patients with Radically Resected Thymomas. Cancer 104 (10), 2063–2071. doi:10.1002/cncr.21433
Cudi, P., Sousan, P., Truffaut, F., Fetouchi, R., Robinet, M., Fadel, E., et al. (2014). Thymoma-associated Myasthenia Gravis: On the Search for a Pathogen Signature. J. Autoimmun. 52, 29–35. doi:10.1016/j.jaut.2013.12.018
Evoli, A., Minisci, C., Di Schino, C., Marsili, F., Punzi, C., Batocechi, A. P., et al. (2002). Thymoma in Patients with MG: Characteristics and Long Term Outcome. Neurology 59 (12), 1844–1850. doi:10.1212/01.wnl.0000032502.89361.0c
Garibaldi, M., Fionda, F., Vanoli, F., Leonardi, L., Loreti, S., Bucci, E., et al. (2020). Muscle Involvement in Myasthenia Gravis: Expanding the Clinical Spectrum of Myasthenia-Myositiss Association from a Large Cohort of Patients. Autoimmun. Rev. 19 (4), 102498. doi:10.1016/j.autrev.2020.102498
Kato, T., Kawaguchi, K., Fukui, T., Nakamura, S., Hakiri, S., Nakatobi, M., et al. (2020). Risk Factors for the Exacerbation of Myasthenic Symptoms after Surgical Therapy for Myasthenia Gravis and Thymoma. Semin. Thorac. Cardiovasc. Surg. 32 (2), 378–385. doi:10.1053/j.semtcvs.2019.09.002
Kim, S. W., and Kim, K.-T. (2020). Expression of Genes Involved in Axon Guidance: How Much Have We Learned? Int. J. Mol. Sci. 21 (10), 3566. doi:10.3390/ijms21103566
Kumar, R. (2015). Myasthenia Gravis and Thymic Neoplasms: A Brief Review. World. J. Clin. Cases. 3 (12), 980–983. doi:10.12998/wjcc.v3.i12.980
Le, F., Luo, P., Ouyang, Q., and Zhong, X. (2020). LncRNA WT1-AS Downregulates Survivin by Upregulating miR-203 in Papillary Thyroid Carcinoma. Cancer Manag. Res. 12, 443–449. doi:10.2147/CMAR.S523294
Luo, Z., Li, Y., Liu, X., Luo, M., Xu, L., Luo, Y., et al. (2015). Systems Biology of Myasthenia Gravis, Integration of Aberrant IncRNA and mRNA Expression Changes. BMC Med. Genomics 8, 13. doi:10.1186/s12920-015-0087-z
Lv, L., Chen, G., Zhou, J., Li, J., and Gong, J. (2015). WT1-AS Promotes Cell Apoptosis in Hepatocellular Carcinoma through Down-Regulating of WT1. J. Exp. Clin. Cancer Res. 34, 119. doi:10.1186/s13046-015-0233-7
Malik, K., Salpekar, A., Hancock, A., Moorwood, K., Jackson, S., Charles, A., et al. (2000). Identification of Differential Methylation of the WT1 Antisense Regulatory Region and Relaxation of Imprinting in Wilms’ Tumor. Cancer Res. 60 (9), 2356–2360.
Mangold, C. A., and Srpapa, M. L. (2019). Persistent Infection with Herpes Simplex Virus 1 and Alzheimer’s Disease–A Call to Study How Variability in Both Virus and Host May Impact Disease. Viruses 11 (10), 966. doi:10.3390/v11100966
Mineo, T. C., Ambrogi, V., Baldi, A., Pompeo, E., and Mineo, D. (2009). Recurrent Thymoma-associated Myasthenia Gravis: On the Search for a Pathogen Signature. J. Autoimmun. 33, 29–35. doi:10.1016/j.jaut.2008.11.048
Mishra, S., Padhi, S., Adhya, A. K., DasMajumdar, S. K., Pattnaik, A., and Chhabra, G. (2021). Peripheral Blood T Lymphocytosis in Thymoma: an Insight into Immunobiology. J. Cancer Res. Clin. Oncol. 147 (1), 295–301. doi:10.1007/s00432-020-03440-2
Nifullayev, S., and Lamarche-Vane, N. (2019). Regulators of Rho GTPases in the Nervous System: Molecular Implication in Axon Guidance and Neurological Disorders. Int. J. Mol. Sci. 20 (6), 1497. doi:10.3390/ijms20061497
Niu, L., Jiang, J., Yin, Y., and Hu, B. (2020). LncRNA XLOC_003810 Modulates Thymic Th17/Treg Balance in Myasthenia Gravis with Thymoma. Clin. Exp. Pharmacol. Physiol. 47 (6), 989–996. doi:10.1111/1440-1681.13280
Oji, Y., Inoue, M., Takeda, Y., Hosen, N., Shintani, Y., Kawakami, M., et al. (2018). WT1 Peptide-Based Immunotherapy for Advanced Thymic Epithelial Malignancies. Int. J. Cancer 142 (11), 2375–2382. doi:10.1002/ijc.31253
Ponnuru, C. P., Oliver, P. L., and Beik, W. (2009). Evolution and Functions of Long Noncoding RNAs. Cell 136 (4), 629–641. doi:10.1016/j.cell.2009.02.006
Qu, G., Tong, W., Jiang, C., Xie, Q., Zou, J., Luo, C., et al. (2020). Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. Technol. Cancer Res. Treat. 19, 1533033820917957. doi:10.1177/1533033820917957
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., et al. (2018). The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer cell 33 (2), 244–258.e10. doi:10.1016/j.ccell.2018.01.003
Raica, M., Cimpean, A. M., and Ribatti, D. (2008). Myasthenia Gravis and the Thymus Gland: A Historical Review. Clin. Exp. Med. 8 (2), 61–64. doi:10.1017/s102308-01518-y.

JZ drafted the manuscript. FH contributed to critical revision of the manuscript for important intellectual content. FH and FL approved the final version of the manuscript. All authors have read and approved the manuscript.

FUNDING
This study was supported by grants from the Fujian Provincial Natural Science Foundation Project (Grant No 2019J01436), Fujian Provincial Health Research Talents Training Programme Medical Innovation Project (Grant No 2019-CX-33) and Joint Funds for the innovation of science and Technology, Fujian province (Grant No 2019Y9022)

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.756493/full#supplementary-material
Russell, S. A., and Bashaw, G. J. (2018). Axon Guidance Pathways and the Control of Gene Expression. Dev. Dyn. 247 (4), 571–580. doi:10.1002/dvdy.24609
Shelly, S., Agmon-Levin, N., Altman, A., and Shoenfeld, Y. (2011). Thymoma and Autoimmunity. Cell Mol Immunol 8 (3), 199–202. doi:10.1038/cmi.2010.74
Singh, S., and Smith, M. J. (2018). RAS GTPase Signalling to Alternative Effector Pathways. Biochem. Soc. Trans. 45 (5), 2214–2252. doi:10.1042/BST20200506
Tan, Y., Zhao, M., Xiang, B., Chang, C., and Lu, Q. (2016). CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases. Clin Rev. Allerg Immunol. 50 (1), 70–83. doi:10.1007/s12016-015-8470-2
Thomachat, M. C. c., Bendriss-Vermare, N., Massacrier, C., Biota, C., Treilleux, L., Goddard, S., et al. (2004). Breast Carcinoma Cells Promote the Differentiation of CD34+ Progenitors towards 2 Different Subpopulations of Dendritic Cells with CD1a-highCD86-Langerin- and CD1a+CD86+Langerin+ Phenotypes. Int. J. Cancer 110 (5), 710–720. doi:10.1002/ijc.20146
Wan, Y., Yao, D., Fang, F., Wang, Y., Wu, G., and Qian, Y. (2021). LncRNA WT1-AS Downregulates lncRNA UCA1 to Suppress Non-small Cell Lung Cancer andPredicts Poor Survival. BMC Cancer 21 (1), 104. doi:10.1186/s12885-020-07767-4
Wang, Q., Ge, X., Zhang, J., and Chen, L. (2020). Effect of IncRNA WT1-AS Regulating WT1 on Oxidative Stress Injury and Apoptosis of Neurons in Alzheimer’s Disease via Inhibition of the miR-375/SIX4 axis. Aging 12 (23), 23974–23995. doi:10.18632/aging.104057
Wu, X., Wu, P., Shen, Y., Jiang, X., and Xu, F. (2018). CD8+ Resident Memory T Cells and Viral Infection. Front. Immunol. 9, 2093. doi:10.3389/fimmu.2018.02093
Xiao, N., Li, C., Liao, W., Yin, J., Zhang, S., Zhang, P., et al. (2021). FOXG1 Mediates the Radiosensitivity of Glioma Cells through Regulation of Autophagy. Int. J. Radiat. Biol. 97 (2), 139–148. doi:10.1080/09553002.2021.1846816
Xu, J.-z., Zhang, J.-l., and Zhang, W.-g. (2018). Antisense RNA: the New Favorite in Genetic Research. J. Zhejiang Univ. Sci. B 19 (10), 739–749. doi:10.1631/jzus.B1700594
Yamada, Y., Weis, C.-A., Thelen, J., Sticht, C., Schalte, B., Strobel, P., et al. (2020). Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes. Front. Immunol. 11, 664. doi:10.3389/fimmu.2020.00664
Yu, L., Ke, J., Du, X., Yu, Z., and Gao, D. (2019). Genetic Characterization of Thymoma. Sci. Rep. 9 (1), 2369. doi:10.1038/s41598-019-38878-z
Yu, W. D., Wang, H., He, Q. F., Xu, Y., and Wang, X. C. (2018). Long Noncoding RNAs in Cancer-immunity Cycle. J. Cel Physiol 233 (9), 6518–6523. doi:10.1002/jcp.26568
Zheng, X., Lin, J., Wu, H., Mo, Z., Lian, Y., Wang, P., et al. (2019). Forkhead Box (FOX) G1 Promotes Hepatocellular Carcinoma Epithelial-Mesenchymal Transition by Activating Wnt Signal through Forming T-Cell Factor-4/Beta-catenin/FOXG1 Complex. J. Exp. Clin. Cancer Res. 38 (1), 475. doi:10.1186/s13046-019-1433-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhuang, Guan, Liu, Liu, Yang, Hu, Lai and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.